Denosumab: Recent update in postmenopausal osteoporosis

Acta Reumatologica Portuguesa

Volumn 37, Issue 4, 2012, Pages 302-313

  Gomes da Silva, Inês Maria Crispim ^a   Branco, Jaime C ^a,b  

^a Centro Hospitalar de Lisboa Ocidental   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Denosumab; Osteoprotegerin; Postmenopausal osteoporosis; Rank; Rankl

Indexed keywords

DENOSUMAB; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; BONE; DRUG ANTAGONISM; DRUG SCREENING; FEMALE; HUMAN; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84876312627     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Moen AD, Kean SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011;28:63-82.
2. Lewiecki EM. Denosumab update. Current Opinion in Rheumatology 2009;21:369-373.
3. Lewiecki EM. Denosumab: an investigational drug for the management of postmenopausal osteoporosis. Biologics: Targets and Therapy 2008;2:645-653.
4. Burge R, Dawson-Hughes B, Solomon DH. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475.
5. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-589.
6. Solomon DH, Morris C, Cheng H, et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 2005;80:194-202.
7. Johnell O, Kanis JA, Odén A, et al. Fracture Risk following an osteoporotic fracture. Osteoporos Int 2004;15:175-179.
8. Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures-a gap in evidence-based practice guideline implementation. Arch Intern Med 2003;163:2165-2172.
9. Deal C. Future therapeutic targets in osteoporosis. Current Opinion in Rheumatology 2009;21:380-385.
10. Charopoulos I, Orme S, Giannoudis P. The role and efficacy of denosumab in the treatment of osteoporosis: an update. Expert Opin Drug Saf;doi:10.1517/ard2010.
11. Geusens P. Emerging treatments for postmenopausal osteoporosis-focus on denosumab. Clinical Interventions in Aging 2009;4:241-250.
12. Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009;41:721-729.
13. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95:1174-1181.
14. Henriksen DB, Alexandersen P, Hartmann B, et al. GLP-2 significantly increases hip BMD in postmenopausal women: a 120-day study. J Bone Miner Res 2007;22(suppl1):S37.
15. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18:923-928.
16. Okazaki M, Potts JT, Gardella TJ. Identification and optimization of residues in PTH and PTHrP that determine altered modes of binding to the PTH/PTHrP receptor. J Bone Miner Res 2008;23:S103.
17. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 2007;45:139-167.
18. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635-2643.
19. Padhi D, Stouch B, Fang L. Antisclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Metab 2007;22 (Suppl 1):S37.
20. Ruckle J, Jacobs M, Kramer W. A single dose of ACE-011 is associated with increases in bone formation and decreases in bone resorption markers in healthy postmenopausal women. J Bone Miner Res 2007;22 (Suppl 1):S38.
21. Romas E. Clinical applications of RANK-ligand inhibition. Internal Medicine Journal 2009;39:110-116.
22. Caetano-Lopes J, Canhão H, Fonseca JE. Osteoblasts and bone formation. Acta Reumatol Port 2007;32:103-110.
23. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives of biochemistry and biophysics 2008;473:139-146.
24. Kong YY, Yoshida H, Sarosi I. OPG is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
25. Li J, Sarosi I, Yan XQ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000; 97:1566-1571.
26. Bucay N, Sarosi, Dunstan CR. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
27. Mizuno A, Amizuka N, Irie K. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-615.
28. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005;208:207-227.
29. Xing L, Schawrz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005;208:19-29.
30. Stolina M, Dwyer D, Morony S. Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum 2005;52:S708.
31. Singer A, Grauer A. Denosumab for the management of postmenopausal osteoporosis. Postgraduate Medicine 2010;122: 176-187.
32. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.
33. Lewiecki EM. Denosumab for joints and bones. Current Rheumatology Reports 2009;11:196-201.
34. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38(2 Suppl 1):S4-9.
35. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-2668.
36. Beckker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-1066.
37. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Eng J Med 2006;354:821-831.
38. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998;246:199-204.
39. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
40. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-4370.
41. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
42. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-448.
43. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 2000;274:281-290.
44. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Drug Discovery 2010;9:767-774.
45. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Research and Therapy 2007:9(Suppl 1):S7(doi:10.1186/ar2171).
46. Scallon Bj, Moore Ma, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995:7:251-259.
47. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5:618-625.
48. Biot J, Fasano C, Santos CD. D'orthoclone au dénosumab-l'expansion des anticorps monoclonaux à des fins thérapeutiques. Medicine Sciences 2009;25:1177-1182.
49. Schett G, Redlich K, Hayer S, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003;48:2042-2051
50. Ross AB, Bateman TA, Kostenuik PJ, et al. The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 2011;12:583-588.
51. Kostenuik PJ, Capparelli C, Morony S, et al. OPG and PTH-(1--34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized mice. Bone 2004;142: 4295-4304.
52. Atkinson JE, Cranmer P, Saunders T. Denosumab (AMG 162), a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res 2005;20(Suppl 1):S294.
53. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alphamediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-792.
54. Kostenuik PJ, Bolon B, Morony S, et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-664.
55. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-289.
56. Byrne FR, Morony S, Warmington K, et al. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 2005;54:78-86.
57. Kostenuik PJ, Warmington K, Grisanti M, et al. RANKL inhibition with (denosumab) AMG 162, a fully human MAb, causes sustained suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Miner Res 2005;20 (Suppl 1):S261.
58. Ferrari SL, Pierroz D, Bonnet N. A comparison of denosumab and alendronate in combination with PTH in ovariectomized knockin mice expressing humanized RANKL. J Bone Miner Res 2007;22(Suppl 1):S37.
59. Beckker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360.
60. Bogado CE, Zanchetta MB, Boailchuk JA, Massari FE, Zanchetta JR. Denosumab: what's new?. Curr Osteoporos Rep 2011;9:12-19.
61. Lewiecki EM, Miller PD, McClung MR, et al. Two-years treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-1841.
62. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on the bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy. A randomized blinded phase 2 clinical trial. Bone 2008;43:222-229.
63. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med 2009;361:756-765.
64. Papapoulos S, Chapurlat R, Brandi ML, et al. Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension. JBMR;2010; DOI-10.1002/jbmr.251.
65. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res2009;24:153-161.
66. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25:72-81.
67. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010;25:2256-2265.
68. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010;25:1886--1894.
69. Block G, Bone HG, Fang L. A single dose study of deonsumab in patients with various degrees of renal impairment. Am J Kid Dis 2010;55:A46.
70. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-2157.
71. Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep 2010;8:163-167.
72. Pageou SC. Denosumab. Landes Bioscience 2009;1:210-215.
73. Lewiecki EM. Clinical use of denosumab for the treatment for postmenopausal osteoporosis. Current Medical Research and Opinion 2010;26:2807-2812.
74. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010;47:34-40.
75. Hiligsmann M, Reginster JY. Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium. Pharmacoeconomics 2011;29:895-911.
76. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE Single Technology Appraisal. Pharmacoeconomics 2011; Epub ahead of print Aug 20.
77. Jönsson B, Ström O, Eisman JA, et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011 Mar;22:967-982. Epub 2010 Oct 9.
78. Pereira JA, Cristino J, Perelmann J, et al. O uso de recursos e custos dos diferentes tipos de fracturas osteoporóticas em Portugal-estimativas na perspectiva do Serviço Nacional de Saúde e do Estado. Acta Reumatol Port 2011;36:31(sup).
79. Cristino J, Canhão H, Perelman J, Santos C, Pereira J. Cost-utility analysis of denosumab versus standard care in the treatment of post-menopausal osteoporosis in Portugal. The Journal of The International Society for Pharmacoeconomics and Outcomes Research 2011;14:A128.
80. Baron R, Ferrari S, Graham R, Russel G. Denosumab and biphosphonates: differents mechanisms of action and effects. Bone 2011;48:677-692.